Jump Financial LLC Purchases New Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Jump Financial LLC bought a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 74,619 shares of the company's stock, valued at approximately $1,406,000. Jump Financial LLC owned 0.10% of Nurix Therapeutics as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Barclays PLC raised its position in shares of Nurix Therapeutics by 77.9% during the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after buying an additional 56,190 shares during the period. Geode Capital Management LLC increased its position in shares of Nurix Therapeutics by 9.6% during the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company's stock worth $32,544,000 after acquiring an additional 126,306 shares during the period. Franklin Resources Inc. boosted its stake in shares of Nurix Therapeutics by 52.4% in the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company's stock valued at $2,766,000 after buying an additional 42,315 shares during the period. Lord Abbett & CO. LLC purchased a new position in Nurix Therapeutics in the third quarter worth approximately $7,879,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock worth $1,531,000 after purchasing an additional 31,352 shares in the last quarter.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX traded up $0.14 during midday trading on Friday, hitting $11.66. The company's stock had a trading volume of 234,960 shares, compared to its average volume of 893,803. The stock's 50 day simple moving average is $12.69 and its 200 day simple moving average is $18.48. The stock has a market capitalization of $888.53 million, a price-to-earnings ratio of -4.03 and a beta of 2.23. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million for the quarter, compared to analyst estimates of $12.78 million. During the same quarter in the previous year, the firm posted ($0.76) EPS. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $488,660.76. The trade was a 14.73 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,326 shares of company stock worth $213,449. Corporate insiders own 7.40% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on NRIX. Stifel Nicolaus cut their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Wells Fargo & Company dropped their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Needham & Company LLC reduced their price objective on shares of Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. Stephens reaffirmed an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Finally, Leerink Partners began coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 price objective for the company. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $30.44.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.